PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New era in transthyretin amyloidosis: From stabilizers to gene editing

2025-08-21
(Press-News.org) Transthyretin amyloidosis (ATTR) is caused by the misfolding and aggregation of the transthyretin (TTR) protein, leading to multi-organ damage. Two main forms exist: hereditary ATTR (ATTRv), linked to TTR gene mutations, and wild-type ATTR (ATTRwt), associated with aging. Historically underdiagnosed, ATTR carried poor prognoses, particularly in advanced cardiac or neuropathic disease. However, the past decade has seen unprecedented therapeutic advances.

Diagnostic Advances Enable Earlier Intervention

Improved detection is a cornerstone of modern ATTR management. Bone scintigraphy, cardiac MRI, echocardiography with strain imaging, and specific biomarkers (NT-proBNP, troponin, neurofilament light chain) facilitate early diagnosis. Genetic testing distinguishes hereditary from wild-type disease, guiding treatment and enabling family screening. Earlier identification allows interventions before irreversible organ damage.

From Liver Transplant to Targeted Pharmacotherapy

Liver transplantation, once the only disease-modifying option for ATTRv, has largely been replaced by pharmacologic agents targeting TTR stability, expression, or amyloid clearance. The three main categories are:

(1) TTR Stabilisers – Drugs such as tafamidis and diflunisal bind to TTR tetramers, preventing dissociation and aggregation. Tafamidis has shown mortality and hospitalisation reduction in ATTR cardiomyopathy (ATTR-ACT trial) and is approved for both ATTRv and ATTRwt cardiomyopathy.

(2) Gene Silencers – RNA interference (siRNA) agents like patisiran and vutrisiran, and antisense oligonucleotides like inotersen and eplontersen, reduce hepatic TTR production. Patisiran's APOLLO trial and vutrisiran's HELIOS trials demonstrated significant improvements in neuropathy scores, quality of life, and cardiac parameters.

(3) Amyloid Clearance Agents – Monoclonal antibodies (e.g., PRX004/NNC6019, NI006) target misfolded TTR and deposits, potentially reversing amyloid burden. Early-phase studies report promising cardiac and neuropathic stabilisation.

Emerging Frontiers: CRISPR-Cas9 Gene Editing

One of the most revolutionary developments is NTLA-2001, a CRISPR-Cas9 therapy designed to permanently inactivate the TTR gene in hepatocytes after a single infusion. Early-phase trials show deep, sustained TTR suppression without major safety concerns over more than two years of follow-up. If successful in larger studies, gene editing could eliminate the need for lifelong therapy.

Therapeutic Pipeline and Regulatory Milestones

Several agents have received FDA and EMA approvals for ATTRv polyneuropathy and cardiomyopathy, including tafamidis, patisiran, vutrisiran, inotersen, eplontersen, and acoramidis. Recent approvals, such as vutrisiran for ATTR cardiomyopathy (2025), reflect growing recognition of ATTR as a treatable cause of heart failure.

Remaining Challenges

Despite these breakthroughs, significant hurdles remain: (1) Access and Cost – Many therapies are expensive and not universally reimbursed, limiting availability. (2) Treatment Sequencing – No head-to-head trials guide whether stabilisers, silencers, or combination therapy is optimal. (3) Late-Stage Disease – Patients with advanced cardiac or neurological damage still face poor outcomes, highlighting the need for regenerative or amyloid-clearing therapies. (4) Long-Term Safety – Gene-based treatments require ongoing monitoring for off-target effects. (5) Presymptomatic Carriers – Guidelines are needed for when to start therapy in mutation carriers before symptoms develop.

Future Outlook

Personalised medicine, integrating genomic data, biomarkers, and multimodality imaging, is likely to define the next era of ATTR care. Multidisciplinary management—uniting neurology, cardiology, genetics, and pharmacology—will be critical. Ongoing clinical trials of CRISPR, monoclonal antibodies, and next-generation silencers aim not only to halt but potentially reverse disease progression.

Conclusion

ATTR has transitioned from a fatal, underdiagnosed disease to one with multiple effective treatment avenues. With continued innovation, early detection, and equitable access, the prognosis for patients with ATTR is set to improve dramatically.

 

See the article:

Anan I. Advances in the treatment of transthyretin amyloidosis. eGastroenterology 2025;3:e100198. doi:10.1136/egastro-2025-100198

 

About eGastroenterology

eGastroenterology is a new, open-access, and open peer-reviewed BMJ Journal, which focuses on basic, clinical, translational, and evidence-based medicine research in all areas of gastroenterology (including hepatology, pancreatology, esophagology, and gastrointestinal surgery). eGastroenterology is now indexed by PubMed, Scopus, CAS, DOAJ, Dimensions, OpenAlex, ROAD, and COPE, with more to come!

For more information, please visit: egastroenterology.bmj.com and follow us on Twitter (@eGastro_BMJ).

Sign-up to Email Alerts for eGastroenterology: https://emails.bmj.com/k/Bmj/jausu/egastroenterology

END



ELSE PRESS RELEASES FROM THIS DATE:

Cumulative hepatitis B surface antigen/hepatitis B virus DNA ratio in immune-tolerant hepatitis B patients

2025-08-21
Background and Aims Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment. This study aimed to investigate changes in the cumulative hepatitis B surface antigen (HBsAg)/HBV DNA ratio in immune-tolerant patients during the transition to the immune-active phase, and to evaluate its potential in predicting the risk of disease progression. Methods This longitudinal study included 127 untreated immune-tolerant patients, who were followed for up to 10 years. An independent cohort of 109 subjects ...

Increased patient-provider communication, education about COPD needed to improve patient care

2025-08-21
Miami (August 21, 2025) – Prioritizing communications between patients and health care providers and increasing patient education about chronic obstructive pulmonary disease (COPD) could help improve patient care, according to a new study. The study is published in the July 2025 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal. COPD is an inflammatory lung disease, comprising several conditions, including chronic bronchitis and emphysema, and can be caused ...

Nation’s leading breast health advocate receives Benjamin Spock Award for Compassion in Medicine

2025-08-21
News Release * Physicians Committee for Responsible Medicine * August 20, 2025 Media contact: Leslie Raabe lraabe@pcrm.org 443 534 5803   Nation’s Leading Breast Health Advocate Receives Benjamin Spock Award for Compassion in Medicine   WASHINGTON, D.C.— Santa Monica Breast Surgeon and Founder of the Pink Lotus Breast Center Kristi Funk, MD, FACS, received the Benjamin Spock Award for Compassion in Medicine at the International Conference on Nutrition and Medicine (ICNM) on Aug. 15. The award was presented by Neal Barnard, MD, president of the Physicians Committee ...

Chung-Ang University researchers demonstrate paper electrode-based crawling soft robots

2025-08-21
Biological systems have inspired the development of next-generation soft robotic systems with diverse motions and functions. Such versatility in soft robots—in terms of rapid and efficient crawling—can be achieved via asymmetric bending through bilayer-type actuators that combine responsive liquid crystal elastomers (LCEs) with flexible substrates. This, in turn, requires temperature-responsive LCEs with accurate temperature regulation via elaborate Joule heating configurations. However, it is a complicated task owing to the difficulty in generating asymmetric motions using isotropic thermal distributions, necessitating simple temperature ...

New tracer could enable surgeons to see and hear prostate cancer

2025-08-21
A preclinical evaluation of a new ’dual-mode’ tracer agent shows promise in not only helping surgeons image and plan prostate cancer procedures, but also provide them with much more consistent and targeted guidance during surgery. The agent uses a single tracer molecule labeled with Fluorine-18—a common isotope used in Positron Emission Tomography (PET) scans—for diagnostic imaging. It also provides a one-step, widely accessible solution that would enable combined fluorescence-guided and radio-guided surgery. “Precision ...

One catalyst, two reactions: Toward more efficient chemical synthesis

2025-08-21
Most of the drugs, plastics, and industrial materials widely used today are produced through chemical reactions. In general, most high-performance and sophisticated substances have complex structures, and their assembly involves multiple chemical reaction steps carried out one after another. This creates significant overhead, as each step requires specific conditions, reagents, and catalysts, as well as considerable energy and labor. Tandem reactions offer a promising solution to this issue. The ...

Regenerative agriculture highlighted as a transformative approach to ecological farming and soil recovery

2025-08-21
A new critical review, published in the journal CABI Agriculture and Bioscience, highlights the emergence and scientific basis of regenerative agriculture – proposing a working definition centred on ecological cycles and farm system outcomes. Dr Nicholas Bardsley, author of the paper from the Department of Agri-Food Economics and Marketing at the University of Reading, suggests that as global agriculture faces intensifying soil degradation, climate disruption, and ecological breakdown, there ...

SLAS Technology unveils AI-powered diagnostics & future lab tech

2025-08-21
Oak Brook, IL – Volume 33 of SLAS Technology, includes one literature highlights column, eight original research articles and four Special Issue (SI) features. Literature Highlights Literature highlights column: From the literature life sciences discovery and technology highlights SLAS Technology Section Editors Jamien Lim, PhD (TDK Electronics, Inc.) and Tal Murthy, PhD (Strain LLC) review noteworthy research articles pertaining to advances in biotechnology, artificial intelligence in science and ...

Hospital stays among migrants in Austria much lower than among Austrians

2025-08-21
Researchers at the Complexity Science Hub (CSH) analyzed 13 million inpatient hospital stays involving around 4 million individuals in Austria: Although about 20% of the population in Austria does not hold Austrian citizenship, this group accounts for only 9.4% of hospital patients and 9.8% of total hospital nights. An estimated 300 million people – about 3.6 percent of the global population – are international migrants. Yet studies consistently show that migrants access healthcare services less frequently ...

Gone but not forgotten: the brain’s map of the body remains unchanged after amputation

2025-08-21
PITTSBURGH, Aug. 21, 2025 – New research from the University of Pittsburgh School of Medicine and Cambridge University upends a long-standing belief about brain plasticity. A study published today in Nature Neuroscience shows that the brain’s built-in “body map” remains stable even when the body undergoes drastic changes, such as the loss of a limb. The findings have implications for the treatment of “phantom limb” pain and suggest that achieving reliable restoration of sensation and controlling robotic replacement limbs via brain-computer interfaces may be more viable in the long term than previously thought. “This study is a powerful ...

LAST 30 PRESS RELEASES:

University of Oklahoma researcher awarded funding to bridge gap between molecular data and tissue architecture

Nationally-recognized pathologist Paul N. Staats, MD, named Chair of Pathology at University of Maryland School of Medicine

The world’s snow leopards are very similar genetically. That doesn’t bode well for their future

Researchers find key to stopping deadly infection

Leafcutter ants have blind spots, just like truck drivers

Tayac receives funding for community engagement project

Parker receives funding for Elementary Education Program Professional Development School (PDS)

Physicists uncork a message in a bottle from another star

Sanders receives funding for project aimed at enabling prostheses for children with lower extremity amputation

Engineers develop solid lubricant to replace toxic materials in farming

Repurposing gemstone polishing waste to create smart cement

Patient-physician messaging by race, ethnicity, insurance type, and preferred language

Unrecognized motor difficulties and developmental coordination disorder in preschool children

Background genetic variants influence clinical features in complex disorders

Smarter battery tech knows whether your EV will make it home

Overactive microRNAs block fat cell development in progeria

Crosswalk confusion: MA drivers flummoxed by pedestrian hybrid beacons, find UMass Amherst researchers

Study shows heart disease mortality disproportionately burdens low-income communities in California

Intracardiac echocardiography recognized as ‘transformative’ imaging modality in new SCAI position statement

Study finds ‘man’s best friend’ slows cellular aging in female veterans

To get representative health data, researchers hand out fitbits

Hiring in high-growth firms: new study explores the timing of organizational changes

Boosting work engagement through a simple smartphone diary

Climate change may create ‘ecological trap’ for species who can’t adapt

Scientists create ChatGPT-like AI model for neuroscience to build one of the most detailed mouse brain maps to date

AI and omics unlock personalized drugs and RNA therapies for heart disease

2023 ocean heatwave ‘unprecedented but not unexpected’

Johns Hopkins researchers develop AI to predict risk of US car crashes

New drug combination offers hope for men with advanced prostate cancer

New discovery finds gene converts insulin-producing cells into blood-sugar boosters

[Press-News.org] New era in transthyretin amyloidosis: From stabilizers to gene editing